RLYB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Rallybio Corp | Needs refresh | Last updated: 2026-04-23T10:26:17Z

TickerRLYB

Market Cap45.2M

Cash RunwayRunway > 12 months

Next Catalystn/a

Public Research Snapshot

Rallybio Corp is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for RLYB116 in a convenient, self-administered at-home solution using Antibody.

Pipeline

Asset	Indication	Modality	Stage	Public Note
RLYB116	a convenient, self-administered at-home solution	Antibody	n/a	Public pipeline row
RLYB332	n/a	Antibody	n/a	Public pipeline row
RLYB114	n/a	n/a	n/a	Public pipeline row
Complement Dysregulation	C5, thereby inhibiting terminal complement activation, and	n/a	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

indication | rare diseases have greatly lagged behind patient needs
indication | rare diseases have greatly lagged behind patient needs
patient_population | patients with rare diseases. Read the Latest Proof that the odds are improving. The RLYB116 confirmatory PK/PD study is expected to p
patient_population | patients with rare diseases. Read the Latest Proof that the odds are improving. The RLYB116 confirmatory PK/PD study is expected to p
target | has

Want the full RLYB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.